Brii Biosciences Presents Positive Data on HBV Combination Therapy at APASL 2026

Key Highlights for Investors

• Brii Biosciences Limited (Stock Code: 2137) presented a cross-study analysis at the prestigious 35th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2026) in Istanbul, Turkey, showcasing data on post-treatment hepatitis B surface antigen (HBsAg) rebound in chronic hepatitis B virus (HBV) infection.
• The analysis focused on participants with prior nucleotide reverse transcriptase inhibitor (NRTI) experience who achieved HBsAg loss in the Phase 2 ENSURE and BRII-179-002 studies.
• The ENSURE study assessed combination approaches using elebsiran and pegylated interferon alfa (PEG-IFNα), with or without BRII-179, aiming to improve functional cure rates in HBV. The BRII-179-002 study evaluated BRII-179 as an add-on to PEG-IFNα.

Detailed Study Findings

• Data pooled from both studies assessed the incidence, magnitude, and clinical relevance of HBsAg rebound after the end of treatment (EOT) with PEG-IFNα alone or in combination with elebsiran or BRII-179.
• Participants demonstrated favorable clinical outcomes after stopping therapy:
• All HBsAg rebounds were below 100 IU/mL, with most (75%) below 10 IU/mL.
• HBV DNA rebound was rare and not linked to clinically meaningful alanine aminotransferase (ALT) elevations after NRTI discontinuation.
• No ALT flares were seen, and only one participant required NRTI retreatment at the investigator’s discretion.
• Key Finding: Shorter NRTI consolidation periods (12–20 weeks vs. 24 weeks) did not increase post-treatment HBsAg rebound rates. This suggests that shortening—or even eliminating—the NRTI consolidation period may be possible in future HBV cure strategies, potentially streamlining treatment and reducing patient burden.

Clinical and Market Significance

• The results provide growing evidence that Brii Biosciences’ novel therapeutic combinations can achieve both rapid HBsAg loss and durable immunological control after therapy withdrawal.
• These findings further support the potential for safe discontinuation of NRTIs in PEG-IFNα-based combination regimens, which could transform the standard of care in HBV treatment.
• Importantly for shareholders, the data strengthens confidence in the company’s pipeline, especially in the potential of BRII-179 and elebsiran as components of next-generation HBV cure strategies. Positive additional readouts are expected throughout 2026, creating potential catalysts for the share price.

Presentation Details

• Title: Cross-study Analysis of HBsAg Rebound Following Treatments of Elebsiran/BRII-179 in Combination with Peginterferon Alfa
• Session: Oral Presentation Session 58
• Date/Time: April 25, 2026, 13:40–15:10 (UTC+3)
• Presenter: Prof. Jidong Jia, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Key Data Points From the Analysis

• Post-EOT HBsAg rebound occurred in 24 of 55 participants (43.6%), with similar rates during NRTI consolidation (23.6%) and after NRTI discontinuation (26.8%).
• Among those with shorter NRTI consolidation (12–20 weeks), only 15% experienced HBsAg rebound after NRTI withdrawal, compared to 23.8% with 24 weeks of consolidation.
• Magnitude of rebound was modest: all <100 IU/mL, and 75% were <10 IU/mL.
• Over 90% of participants maintained HBV DNA below the lower limit of quantification at last visit.

Cautionary Statement for Investors

Shareholders should note: There is no assurance that BRII-179 and elebsiran will ultimately be successfully developed or marketed by Brii Biosciences. Investors should exercise caution and consult professional or financial advisers when considering any investment decisions regarding the company’s shares.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. Investors are urged to conduct their own due diligence.

View BRII-B Historical chart here